Areas of Focus
- Pharmacology
- Oncology Pharmacology
Work Experience
- 2013-10 to 2016-06 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
- 2013-07 to 2013-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
- 2011-05 to 2013-06 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
- 2008-10 to 2010-12 - Karolinska Institute - Joint PhD
- 2007-09 to 2010-12 - Jilin University - PhD
- 2004-09 to 2007-06 - Jilin University - Master's
- 2000-09 to 2004-06 - Jilin University - Bachelor's
Academic Background & Achievements
- 2008-10 to 2010-12 Joint PhD: Karolinska Institute
- 2007-09 to 2010-12 PhD: Jilin University
- 2004-09 to 2007-06 Master's: Jilin University
- 2000-09 to 2004-06 Bachelor's: Jilin University
Publications
- Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities, 9th Author, 2022
- Discovery of a series of 1H-pyrrolo2,3-bpyridine compounds as potent TNIK inhibitors, 4th Author, 2021
- Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1, 9th Author, 2021
- A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction, 12th Author, 2020
- Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter, 4th Author, 2020
- Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors, 17th Author, 2019
- Inhibition of the BET family reduces its new target gene IDO1 expression and the production of l -kynurenine, 8th Author, 2019
- New microtubulin inhibitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis, 7th Author, 2018
- Structural Modification of Natural Product Tanshinone I Leading to Discovery of Novel Nitrogen-Enriched Derivatives with Enhanced Anticancer Profile and Improved Drug-like Properties, 6th Author, 2018
- New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis, 4th Author, 2018
- Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups, 2nd Author, 2018
- Low, but not high, dose caffeine is a readily available probe for adenosine actions, 3rd Author, 2017
- Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution, 6th Author, 2017
- Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials, 9th Author, 2017
- Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor, 2nd Author, 2017
- Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced invivo efficacy for cancer therapy, 10th Author, 2017
- Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy, 5th Author, 2017
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy, 1st Author, 2016
- Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44, 5th Author, 2016
- Dual targeting of microtubule and topoisomerase II by alpha-carboline derivative YCH337 for tumor proliferation and growth inhibition, 10th Author, 2015
- Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1�� accumulation in both endothelial and tumor cells, 3rd Author, 2015
- 微管与拓扑异构酶Ⅱ双靶点抑制剂YCH337的抗肿瘤作用与机制研究, 10th Author, 2015
- Dual targeting of microtubule and topoisomerase II by ��-carboline derivative YCH337 for tumor proliferation and growth inhibition, 10th Author, 2015
- Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1a accumulation in both endothelial and tumor cells, 3rd Author, 2015
- 丹参酮Ⅰ抗血管生成作用和机制研究, 3rd Author, 2015
- Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization, 2nd Author, 2015
- Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization, 2nd Author, 2015
- Energy homeostasis in mice lacking adenosine receptors, 1st Author, 2014
- MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189, 2nd Author, 2014
- Marine-Derived Angiogenesis Inhibitors for Cancer Therapy, 1st Author, 2013
- Marine-Derived Angiogenesis Inhibitors for Cancer Therapy, 1st Author, 2013
- Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain, 4th Author, 2013
- Natural Product Triptolide Mediates Cancer Cell Death by Triggering CDK7-Dependent Degradation of RNA Polymerase II, 3rd Author, 2012
- Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs, Not mentioned, 2012
- Differential sensitivity of RIP3-proficient and deficient murine fibroblasts to camptothecin anticancer drugs, 2nd Author, 2012
- Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model, 4th Author, 2012
- Chapter 3 - Adenosine and the Regulation of Metabolism and Body Temperature, 3rd Author, 2011
- Adenosine A(1) receptors and vascular reactivity, Not mentioned, 2010
- Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury, 3rd Author
